Salicylic acid

Description

The product is identified by SPL code 34089-3 and is presented as a white to off-white, round, biconvex tablet. Each tablet is debossed with "A" on one side and "123" on the other side, containing 500 mg of Acetaminophen. The formulation includes the following inactive ingredients: microcrystalline cellulose, croscarmellose sodium, magnesium stearate, hypromellose, titanium dioxide, polyethylene glycol, talc, iron oxide red, and iron oxide yellow.

Uses and Indications

This drug is indicated for external use only. There are no teratogenic effects associated with its use, nor are there any nonteratogenic effects reported.

Dosage and Administration

The product is intended for external use only. Healthcare professionals should ensure that the medication is applied exclusively to the affected area of the skin. Prior to application, the area should be cleaned and dried thoroughly.

The recommended dosage and frequency of administration will depend on the specific condition being treated. It is essential to follow the prescribed dosing regimen, which may vary based on individual patient needs and response to therapy.

Healthcare professionals should instruct patients to apply the medication as directed, avoiding contact with eyes, mucous membranes, and open wounds. If irritation or an adverse reaction occurs, patients should be advised to discontinue use and consult their healthcare provider.

For optimal results, adherence to the prescribed treatment plan is crucial, and any adjustments to the dosage or frequency should be made under the guidance of a qualified healthcare professional.

Contraindications

Use is contraindicated in patients who experience any irritation or adverse reaction. Application should be discontinued on broken or irritated scalp to prevent exacerbation of the condition. Additionally, contact with the eyes should be avoided; in the event of contact, the eyes must be rinsed thoroughly with water.

Warnings and Precautions

It is imperative to keep this product out of reach of children to prevent accidental ingestion. In the event of swallowing, immediate medical assistance should be sought, or the local Poison Control Center should be contacted without delay.

Users should discontinue use if any signs of irritation or rash develop. This includes stopping use on broken or irritated scalp areas. Additionally, if any irritation or adverse reaction occurs during use, it is essential to cease application of the product.

Care should be taken to avoid contact with the eyes while using this product. Should contact occur, it is crucial to rinse the eyes thoroughly with water. Discontinuation of use is advised if any irritation or adverse reaction arises following eye contact.

Side Effects

Patients should discontinue use of the product if signs of irritation or rash occur. It is important to note that the product should not be applied to a broken or irritated scalp, as this may exacerbate adverse reactions.

In clinical practice, monitoring for these reactions is essential to ensure patient safety and to mitigate any potential complications associated with the use of the product.

Drug Interactions

No drug interactions or drug and laboratory test interactions have been identified for this product. Therefore, no specific recommendations for dosage adjustments or monitoring are necessary at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Skin Tag Patches. Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children to prevent accidental ingestion. In the event of irritation, use should be discontinued immediately. It is important to instruct pediatric patients not to swallow the medication.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

There is no specific information available regarding the use of this drug during pregnancy, including safety concerns, dosage modifications, or special precautions. Healthcare professionals should consider the lack of data when prescribing this medication to pregnant patients. It is advisable to weigh the potential benefits against any unknown risks to fetal outcomes. Women of childbearing potential should be counseled on the importance of effective contraception during treatment and the need to inform their healthcare provider if they become pregnant or plan to become pregnant while using this medication.

Lactation

There is no information available regarding the use of this drug in lactating mothers or its effects on breastfed infants. Healthcare professionals should consider the absence of data when advising lactating mothers about the use of this medication.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the event of an overdosage, there is currently no specific information available regarding the effects or management of such an occurrence. Healthcare professionals are advised to monitor the patient closely for any unusual symptoms and to provide supportive care as necessary.

Given the absence of detailed guidance, it is recommended that healthcare providers consult local poison control centers or relevant medical authorities for further assistance in managing potential overdosage situations. Continuous assessment of the patient's condition is essential to ensure appropriate interventions are implemented promptly.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in question. Further studies may be necessary to fully evaluate the nonclinical toxicology profile.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the product is swallowed. It is important for patients to understand the potential risks associated with ingestion and the need for prompt action.

Patients should be instructed to discontinue use of the product if they experience any irritation or adverse reactions. This precaution is essential to ensure their safety and well-being while using the product.

Additionally, healthcare providers should emphasize the importance of avoiding contact with the eyes during use. In the event of accidental contact, patients should rinse their eyes thoroughly with water and discontinue use if any irritation or adverse reaction occurs. This guidance will help patients manage any unintended exposure effectively.

Storage and Handling

The product is supplied in a container that must be kept tightly closed to maintain integrity. It should be stored at a temperature range of 20°C to 25°C (68°F to 77°F) and protected from light to prevent degradation. Once opened, the product should be discarded to ensure safety and efficacy.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Skin Tag Patches, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)